Key facts
- Aquilon Pharma’s last known valuation is $8.0M (Dec 2024).
- It has raised $4.7M; the latest was Later Stage VC ($1.9M) in Dec 2024.
- Notable investors include Noshaq, SambrInvest, Be Angels, Scale Investment Funds.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Aquilon Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Aquilon Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aquilon Pharma
Developer of pharmaceutical drugs designed to offer the treatment of pulmonary diseases. The company focuses on developing drugs for the treatment of respiratory disorders and enhances both the lung deposition and the pharmacology of existing drugs for asthma and chronic obstructive pulmonary disease, enabling patients to get efficient inhalation drugs for respiratory problems.
- Sector
- Healthcare
- HQ
- Liege, Belgium
- Founded
- 2011
- Employees
- 22
- Website
- aquilonpharma.com/
- Ownership
- Privately Held (backing)
Aquilon Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aquilon Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aquilon Pharma in its N-PORT filings yet. We sweep new filings monthly.